华芢生物创新药助力降低医疗负担,获资本与市场双重认可

极目新闻
Dec 18, 2025

深耕创面愈合领域的华芢生物,PDGF(血小板衍生生长因子)药物核心技术持续突破,核心产品Pro-101-2候选药临床进程顺利推进。同时公司港股上市进入新阶段,开启技术产业化与市场扩张的双重征程。作为破解糖尿病足溃疡难愈合痛点的关键药物,华芢生物自主研发的Pro-101-2候选药展现出突出技术优势。PDGF的临床价值已获国际公认,其通过刺激细胞增殖、促进血管再生的作用机制,能针对性解决糖足治疗难题。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10